Up to $28.6 million in borrowing capacity through May 2029 WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), a healthcare company focused on
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare
WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and
WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it will operate under the name Tevogen Inc., following approval by
WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) announced that its 2026 Annual Meeting of Stockholders (the "Annual Meeting)" is
William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Tevogen
WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its
WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent ("LoI") to
WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on building a
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that it has entered into a securities purchase agreement for a private investment in
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including
Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates across 20+ countries,
WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the
WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the
